84 related articles for article (PubMed ID: 9623741)
1. Somatostatin analogues in the treatment of thyroid eye disease.
Krassas GE
Thyroid; 1998 May; 8(5):443-5. PubMed ID: 9623741
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin receptor scintigraphy before and after treatment with somatostatin analogues in patients with thyroid eye disease.
Krassas GE; Doumas A; Kaltsas T; Halkias A; Pontikides N
Thyroid; 1999 Jan; 9(1):47-52. PubMed ID: 10037076
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin analogs: a new tool for the management of Graves' ophthalmopathy.
Krassas GE
J Endocrinol Invest; 2004 Mar; 27(3):281-7. PubMed ID: 15165005
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of tumor necrosis factor-alpha, soluble intercellular adhesion molecule-1, soluble vascular cell adhesion molecule-1, and soluble interleukin-1 receptor antagonist in patients with thyroid eye disease undergoing treatment with somatostatin analogues.
Krassas GE; Pontikides N; Doukidis D; Heufelder G; Heufelder AE
Thyroid; 2001 Dec; 11(12):1115-22. PubMed ID: 12186498
[TBL] [Abstract][Full Text] [Related]
5. Lanreotide in the treatment of patients with thyroid eye disease.
Krassas GE; Kaltsas T; Dumas A; Pontikides N; Tolis G
Eur J Endocrinol; 1997 Apr; 136(4):416-22. PubMed ID: 9150703
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease.
Krassas GE; Dumas A; Pontikides N; Kaltsas T
Clin Endocrinol (Oxf); 1995 Jun; 42(6):571-80. PubMed ID: 7634496
[TBL] [Abstract][Full Text] [Related]
7. Ophthalmic complications in juvenile Graves' Disease - clinic and therapeutic approaches.
Krassas GE
Pediatr Endocrinol Rev; 2003 Dec; 1 Suppl 2():223-9; discussion 229. PubMed ID: 16444162
[TBL] [Abstract][Full Text] [Related]
8. Corticosteroids in the medical treatment of thyroid ophthalmopathy: when and how? Somatostatin analogues: where we stand today.
Krassas GE; Gogakos A; Boboridis K
Pediatr Endocrinol Rev; 2010 Mar; 7 Suppl 2():204-9. PubMed ID: 20467364
[TBL] [Abstract][Full Text] [Related]
9. [111In-DTPA-D-Phe1] octreotide scintigraphy in thyroidal and orbital Graves' disease: a parameter for disease activity?
Postema PT; Krenning EP; Wijngaarde R; Kooy PP; Oei HY; van den Bosch WA; Reubi JC; Wiersinga WM; Hooijkaas H; van der Loos T
J Clin Endocrinol Metab; 1994 Dec; 79(6):1845-51. PubMed ID: 7989493
[TBL] [Abstract][Full Text] [Related]
10. Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy.
Colao A; Lastoria S; Ferone D; Pivonello R; Macchia PE; Vassallo P; Bonavolonta G; Muto P; Lombardi G; Fenzi G
J Clin Endocrinol Metab; 1998 Nov; 83(11):3790-4. PubMed ID: 9814448
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
Giusti M; Gussoni G; Cuttica CM; Giordano G
J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
[TBL] [Abstract][Full Text] [Related]
12. The role of octreoscan in thyroid eye disease.
Krassas GE; Kahaly GJ
Eur J Endocrinol; 1999 May; 140(5):373-5. PubMed ID: 10229898
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of immunological mechanisms mediating thyroid-associated ophthalmopathy by radionuclide imaging using the somatostatin analog 111In-octreotide.
Moncayo R; Baldissera I; Decristoforo C; Kendler D; Donnemiller E
Thyroid; 1997 Feb; 7(1):21-9. PubMed ID: 9086565
[TBL] [Abstract][Full Text] [Related]
14. Management of thyroid eye disease.
Bartalena L; Marcocci C; Tanda L; Pinchera A
Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S458-65. PubMed ID: 12192546
[TBL] [Abstract][Full Text] [Related]
15. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
Morange I; De Boisvilliers F; Chanson P; Lucas B; DeWailly D; Catus F; Thomas F; Jaquet P
J Clin Endocrinol Metab; 1994 Jul; 79(1):145-51. PubMed ID: 8027218
[TBL] [Abstract][Full Text] [Related]
16. [Therapy with somatostatin analogs in patient with orbitopathy and positive Octreoscan].
Pichler R; Maschek W; Holzinger C
Acta Med Austriaca; 2001; 28(4):99-101. PubMed ID: 11593900
[TBL] [Abstract][Full Text] [Related]
17. [Octreotide scintigraphy in thyroid orbitopathy].
Aguirre-Balsalobre F; Mengual-Verdú E; Muñoz-Acosta JM; Martínez-Caballero A; Caballero-Carpena O; Hueso-Abacens JR
Arch Soc Esp Oftalmol; 2007 Mar; 82(3):133-9. PubMed ID: 17357889
[TBL] [Abstract][Full Text] [Related]
18. Thyroid-associated ophthalmopathy in juvenile Graves' disease--clinical, endocrine and therapeutic aspects.
Krassas GE; Gogakos A
J Pediatr Endocrinol Metab; 2006 Oct; 19(10):1193-206. PubMed ID: 17172081
[TBL] [Abstract][Full Text] [Related]
19. [Somatostatin and the digestive system. Clinical experiences].
Herszényi L; Mihály E; Tulassay Z
Orv Hetil; 2013 Sep; 154(39):1535-40. PubMed ID: 24058098
[TBL] [Abstract][Full Text] [Related]
20. Graves' dermopathy: does octreotide scintigraphy predict the response to octreotide treatment?
Kuyvenhoven JP; van der Pijl JW; Goslings BM; Wiersinga WM
Thyroid; 1996 Oct; 6(5):385-9. PubMed ID: 8936660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
